NASDAQ:MGLN
Overall MGLN gets a fundamental rating of 2 out of 10. We evaluated MGLN against 101 industry peers in the Health Care Providers & Services industry. MGLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MGLN is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9% | ||
| ROE | 15.61% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.03% | ||
| PM (TTM) | 6.26% | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.8 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.92 | ||
| Quick Ratio | 2.86 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.15 | ||
| Fwd PE | 27.31 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 12.26 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
94.99
0 (0%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 87.15 | ||
| Fwd PE | 27.31 | ||
| P/S | 0.51 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.27 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.26 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9% | ||
| ROE | 15.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 1.03% | ||
| PM (TTM) | 6.26% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.92 | ||
| Quick Ratio | 2.86 | ||
| Altman-Z | 3.8 |
ChartMill assigns a fundamental rating of 5 / 10 to MGLN.
ChartMill assigns a valuation rating of 2 / 10 to MAGELLAN HEALTH INC (MGLN). This can be considered as Overvalued.
MAGELLAN HEALTH INC (MGLN) has a profitability rating of 6 / 10.
The Earnings per Share (EPS) of MAGELLAN HEALTH INC (MGLN) is expected to grow by 11.05% in the next year.